Nonalcoholic Fatty Liver Disease

Lingling Ding; Yvonne Oligschlaeger; Ronit Shiri-Sverdlov; Tom Houben

doi:10.1007/164_2020_352

Nonalcoholic Fatty Liver Disease

Lingling Ding, Yvonne Oligschlaeger, Ronit Shiri-Sverdlov, Tom Houben

NUTRIM - Liver and digestive health

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

Abstract

Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

Original language	English
Title of host publication	Prevention and Treatment of Atherosclerosis
Subtitle of host publication	Improving State-of-the-Art Management and Search for Novel Targets
Editors	Arnold von Eckardstein, Christoph J. Binder
Publisher	Springer
Chapter	2
Pages	233-269
Number of pages	37
Volume	270
DOIs	https://doi.org/10.1007/164_2020_352
Publication status	Published - 2022

Publication series

Series	Handbook of Experimental Pharmacology
ISSN	0171-2004

Keywords

Humans
Metabolic Syndrome/epidemiology
Non-alcoholic Fatty Liver Disease/drug therapy

Access to Document

10.1007/164_2020_352Licence: CC BY

Cite this

@inbook{d766c83fc2664fdead8886b7b5ce6b69,

title = "Nonalcoholic Fatty Liver Disease",

abstract = "Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.",

keywords = "Humans, Metabolic Syndrome/epidemiology, Non-alcoholic Fatty Liver Disease/drug therapy",

author = "Lingling Ding and Yvonne Oligschlaeger and Ronit Shiri-Sverdlov and Tom Houben",

note = "{\textcopyright} 2020. The Author(s).",

year = "2022",

doi = "10.1007/164_2020_352",

language = "English",

volume = "270",

series = "Handbook of Experimental Pharmacology",

publisher = "Springer",

pages = "233--269",

editor = "{von Eckardstein}, Arnold and Binder, {Christoph J.}",

booktitle = "Prevention and Treatment of Atherosclerosis",

address = "United States",

}

Nonalcoholic Fatty Liver Disease. / Ding, Lingling; Oligschlaeger, Yvonne; Shiri-Sverdlov, Ronit et al.
Prevention and Treatment of Atherosclerosis: Improving State-of-the-Art Management and Search for Novel Targets. ed. / Arnold von Eckardstein; Christoph J. Binder. Vol. 270 Springer, 2022. p. 233-269 (Handbook of Experimental Pharmacology).

Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic

TY - CHAP

T1 - Nonalcoholic Fatty Liver Disease

AU - Ding, Lingling

AU - Oligschlaeger, Yvonne

AU - Shiri-Sverdlov, Ronit

AU - Houben, Tom

PY - 2022

Y1 - 2022

N2 - Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

AB - Nonalcoholic fatty liver disease (NAFLD) is considered the hepatic manifestation of the metabolic syndrome (MetS) and comprises one of the largest health threats of the twenty-first century. In this chapter, we review the current state of knowledge of NAFLD and underline the striking similarities with atherosclerosis. We first describe current epidemiological data showing the staggering increase of NAFLD numbers and its related clinical and economic costs. We then provide an overview of pathophysiological hepatic processes in NAFLD and highlight the systemic aspects of NAFLD that point toward metabolic crosstalk between organs as an important cause of metabolic disease. Finally, we end by highlighting the currently investigated therapeutic approaches for NAFLD, which also show strong similarities with a range of treatment options for atherosclerosis.

KW - Humans

KW - Metabolic Syndrome/epidemiology

KW - Non-alcoholic Fatty Liver Disease/drug therapy

U2 - 10.1007/164_2020_352

DO - 10.1007/164_2020_352

M3 - Chapter

C2 - 32185502

VL - 270

T3 - Handbook of Experimental Pharmacology

SP - 233

EP - 269

BT - Prevention and Treatment of Atherosclerosis

A2 - von Eckardstein, Arnold

A2 - Binder, Christoph J.

PB - Springer

ER -